Proteros and CHDI Establish Discovery Services Collaboration to Address Huntington’s Disease
Complete the form below to unlock access to ALL audio articles.
Proteros Biostructures GmbH has announced that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI.
Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD).
Cony D’Cruz Chief Business Officer and President Proteros US, Inc. stated, “CHDI has been at the forefront of using a best-in-class network to assist in developing therapies for HD. We welcome the opportunity for Proteros to contribute to this effort.”